![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The launch of Nexiclon XR, the only once-daily clonidine extended-release tablets is based on Tris's LiquiXR drug delivery technology, which has led to the development of multiple first-in-category products indicated for treatment of hypertension.
Lead Product(s): Clonidine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexiclon
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
This partnership aligns perfectly with Sabal’s mission to support commercial launch for two products, Nexiclon™ XR and Fibricor®, by helping them deliver their products to physicians and patients who need them.
Lead Product(s): Clonidine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nexiclon XR
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sabal Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 22, 2022
Details:
The licensed product upon launch, will be the only once-daily formulation containing an established Active Pharmaceutical Ingredient (API), which physicians can optionally prescribe alone or concomitantly with other antihypertensive agents to pursue desired outcomes.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Tris Pharma Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2021
Details:
USFDA has approved QDOLO™ (tramadol hydrochloride) Oral Solution 5mg/1mL C-IV, an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Tramadol Hydrochloride
Therapeutic Area: Neurology Product Name: Qdolo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020